Endometrial Adenocarcinoma clinical trials

Explore recruiting endometrial adenocarcinoma clinical trials.

Recruiting endometrial adenocarcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Endometrial Adenocarcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2 Study of ACR-368 Therapy in Subjects with Endometrial Cancer

Italy, Germany, Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

TREAT-EC (Tirzepatide in the treatment of endometrial cancer) - a clinical trial

Ireland

Therapeutic exploratory (Phase II) EU CTIS Study details

VICTORIA (hormone receptor postiVe endometrIal Carcinoma treated by dual mTORC1/mTORC2 Inhibitor and Anastrozole):A Multicentric, randomized, non comparative, open-label Phase I/II evaluating AZD2014 (dual mTORC1/mTORC2 inhibitor) in combination with anastrozole versus anastrozole alone in the treatment of metastatic hormone receptor-positive endometrial adenocarcinoma

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301)

France, Hungary, Romania, Spain, Netherlands, Finland +9 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1/2, Multicenter, Open Label, Dose Escalation and Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients with Unresectable Locally Advanced or Metastatic Cancer

Belgium, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients with Unresectable Locally Advanced or Metastatic Cancer

Spain, Belgium

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Endometrial Adenocarcinoma trials by city

Endometrial Adenocarcinoma in Toronto Endometrial Adenocarcinoma in Vancouver Endometrial Adenocarcinoma in Montreal Endometrial Adenocarcinoma in Calgary Endometrial Adenocarcinoma in Edmonton Endometrial Adenocarcinoma in Ottawa Endometrial Adenocarcinoma in Winnipeg Endometrial Adenocarcinoma in Quebec City Endometrial Adenocarcinoma in Hamilton Endometrial Adenocarcinoma in Kitchener Endometrial Adenocarcinoma in London Endometrial Adenocarcinoma in Halifax Endometrial Adenocarcinoma in New York Endometrial Adenocarcinoma in Los Angeles Endometrial Adenocarcinoma in Chicago Endometrial Adenocarcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease